Campbell & CO Investment Adviser LLC Grows Holdings in Twist Bioscience Corporation $TWST

Campbell & CO Investment Adviser LLC grew its position in shares of Twist Bioscience Corporation (NASDAQ:TWST) by 227.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 47,200 shares of the company’s stock after purchasing an additional 32,792 shares during the period. Campbell & CO Investment Adviser LLC owned 0.08% of Twist Bioscience worth $1,328,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. boosted its position in Twist Bioscience by 15.0% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,315 shares of the company’s stock worth $85,000 after acquiring an additional 302 shares during the last quarter. D.A. Davidson & CO. lifted its stake in shares of Twist Bioscience by 1.5% during the 2nd quarter. D.A. Davidson & CO. now owns 23,062 shares of the company’s stock worth $848,000 after purchasing an additional 352 shares during the period. California State Teachers Retirement System lifted its stake in shares of Twist Bioscience by 0.8% during the 2nd quarter. California State Teachers Retirement System now owns 54,187 shares of the company’s stock worth $1,994,000 after purchasing an additional 442 shares during the period. Vanguard Personalized Indexing Management LLC boosted its holdings in shares of Twist Bioscience by 8.4% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 6,031 shares of the company’s stock worth $222,000 after purchasing an additional 469 shares during the last quarter. Finally, Police & Firemen s Retirement System of New Jersey grew its position in shares of Twist Bioscience by 4.9% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 13,471 shares of the company’s stock valued at $496,000 after purchasing an additional 627 shares during the period.

Insider Buying and Selling

In other Twist Bioscience news, insider Dennis Cho sold 1,019 shares of the company’s stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $32.08, for a total value of $32,689.52. Following the completion of the transaction, the insider owned 120,694 shares in the company, valued at $3,871,863.52. This represents a 0.84% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Adam Laponis sold 3,000 shares of the stock in a transaction that occurred on Tuesday, January 13th. The shares were sold at an average price of $40.00, for a total transaction of $120,000.00. Following the completion of the sale, the chief financial officer directly owned 137,031 shares of the company’s stock, valued at $5,481,240. This trade represents a 2.14% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 66,437 shares of company stock valued at $2,136,365. 3.08% of the stock is owned by insiders.

Twist Bioscience Price Performance

Twist Bioscience stock opened at $41.41 on Friday. The firm has a fifty day moving average of $32.42 and a 200-day moving average of $31.26. Twist Bioscience Corporation has a 52-week low of $23.30 and a 52-week high of $55.33. The company has a quick ratio of 3.33, a current ratio of 3.64 and a debt-to-equity ratio of 0.03. The firm has a market capitalization of $2.54 billion, a P/E ratio of -31.61 and a beta of 2.19.

Twist Bioscience (NASDAQ:TWST) last posted its earnings results on Friday, November 14th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.05). Twist Bioscience had a negative net margin of 20.63% and a negative return on equity of 27.40%. The business had revenue of $99.01 million for the quarter, compared to analyst estimates of $97.40 million. As a group, analysts predict that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the company. TD Cowen raised their price target on Twist Bioscience from $32.00 to $43.00 and gave the stock a “buy” rating in a research note on Thursday, January 8th. Barclays raised their target price on shares of Twist Bioscience from $37.00 to $39.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. Cowen restated a “buy” rating on shares of Twist Bioscience in a report on Thursday, January 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Twist Bioscience in a research note on Monday, December 29th. Finally, Stephens started coverage on shares of Twist Bioscience in a research note on Monday, November 3rd. They set an “overweight” rating and a $41.00 price objective for the company. Nine research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Twist Bioscience presently has a consensus rating of “Moderate Buy” and an average price target of $44.67.

Twist Bioscience Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.